Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
Lyell Immunopharma (LYEL) Stock Price & Analysis
67 Followers
LYEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.18 - $3.41
Previous Close$1.45
Volume661.47K
Average Volume (3M)1.09M
Market Cap
$369.66M
Enterprise Value-$119.67M
Total Cash (Recent Filing)$546.22M
Total Debt (Recent Filing)$56.89M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 07, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding254,939,222
10 Day Avg. Volume931,165
30 Day Avg. Volume1,089,063
Standard Deviation0.25
R-Squared0.00695
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.80
Price to Sales (P/S)4020.20
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-920.52
Enterprise Value/Gross Profit-920.52
Enterprise Value/Ebitda0.52
Forecast
1Y Price Target
$3.50Price Target Upside141.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Lyell Immunopharma News
Bulls Say, Bears Say
Bulls Say
Clinical DataLYL797 (ROR1 CAR-T) initial clinical data in ROR1+ solid tumors expected in the near future.
Efficacy SignalsEncouraging early signals of efficacy, including dose-dependent activity in TNBC patients, with some experiencing confirmed partial responses.
Financial PositionLyell ended 1Q24 with $526M in cash, which management expects to provide an operational runway into 2027.
Bears Say
Adverse EventsCommon Grade 3+ adverse events, including pneumonitis, resulted in a death, leading to dosing down-titration for those with lung involvements.
Clinical ActivityRobust clinical activity is not being observed with the platform, raising concerns about its prospects.
Safety ConcernsWidespread pneumonitis observed in patients with lung involvement, leading to an instance of Grade 5 respiratory failure.
---
Ownership Overview
43.99% Insiders
11.92% Mutual Funds
36.81% Other Institutional Investors
7.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $1.18 and its highest was $3.41 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Currently, no data Available
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Aug 07, 2024 which is in 31 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on May 06, 2024. The company reported -$0.239 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.019.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -$0.2.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 254,939,220 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$0.239 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went up 7.627%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Among the largest hedge funds holding Lyell Immunopharma’s share is Caxton Associates LP. It holds Lyell Immunopharma’s shares valued at 389K.
---
Lyell Immunopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (141.38% Upside)
$3.50 (141.38% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 93.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.92%
12-Months-Change
Fundamentals
Return on Equity
-32.93%
Trailing 12-Months
Asset Growth
-21.15%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
---
LYEL Stock 12 Month Forecast
Average Price Target
$3.50
▲(141.38% Upside)
Technical Analysis
Best Analysts Covering LYEL
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+11.10%
reiterated a buy rating 12 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.10% per trade.
---